Novocure Profitability Analysis

NVCR Stock  USD 13.12  0.19  1.47%   
Based on the measurements of profitability obtained from Novocure's financial statements, Novocure may not be well positioned to generate adequate gross income at this time. It has a very high probability of underperforming in February. Profitability indicators assess Novocure's ability to earn profits and add value for shareholders.
 
Net Loss  
First Reported
2013-12-31
Previous Quarter
-40.1 M
Current Value
-37.3 M
Quarterly Volatility
18.8 M
 
Yuan Drop
 
Covid
At this time, Novocure's Days Sales Outstanding is relatively stable compared to the past year. As of 01/03/2026, Sales General And Administrative To Revenue is likely to grow to 0.64, while EV To Sales is likely to drop 6.74. At this time, Novocure's Total Other Income Expense Net is relatively stable compared to the past year. As of 01/03/2026, Income Tax Expense is likely to grow to about 45.2 M, though Operating Income is likely to grow to (145.8 M). As of 01/03/2026, Gross Profit is likely to grow to about 565.2 M, though Pretax Profit Margin is likely to grow to (0.20).
Current ValueLast YearChange From Last Year 10 Year Trend
Gross Profit Margin0.50.7
Way Down
Slightly volatile
For Novocure profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Novocure to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Novocure utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Novocure's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Novocure over time as well as its relative position and ranking within its peers.
Check out Correlation Analysis.
To learn how to invest in Novocure Stock, please use our How to Invest in Novocure guide.The next projected EPS of Novocure is estimated to be -0.345725 with future projections ranging from a low of -0.375 to a high of -0.3275. Novocure's most recent 12-month trailing earnings per share (EPS TTM) is at -1.61. Please be aware that the consensus of earnings estimates for Novocure is based on EPS before non-recurring items and includes expenses related to employee stock options.
 
Yuan Drop
 
Covid
Novocure is projected to generate -0.345725 in earnings per share on the 31st of December 2025. Novocure earnings estimates show analyst consensus about projected Novocure EPS (Earning Per Share). It derives the highest and the lowest estimates based on Novocure's historical volatility. Many public companies, such as Novocure, manage the perception of their earnings on a regular basis to make sure that analyst estimates are accurate. Future earnings calculations are also an essential input when attempting to value a firm. By analyzing Novocure's earnings estimates, investors can diagnose different trends across Novocure's analyst sentiment over time as well as compare current estimates against different timeframes.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Novocure. If investors know Novocure will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Novocure listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
(0.06)
Earnings Share
(1.61)
Revenue Per Share
5.811
Quarterly Revenue Growth
0.078
Return On Assets
(0.08)
The market value of Novocure is measured differently than its book value, which is the value of Novocure that is recorded on the company's balance sheet. Investors also form their own opinion of Novocure's value that differs from its market value or its book value, called intrinsic value, which is Novocure's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Novocure's market value can be influenced by many factors that don't directly affect Novocure's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Novocure's value and its price as these two are different measures arrived at by different means. Investors typically determine if Novocure is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Novocure's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Novocure Return On Asset vs. Return On Equity Fundamental Analysis

Comparative valuation techniques use various fundamental indicators to help in determining Novocure's current stock value. Our valuation model uses many indicators to compare Novocure value to that of its competitors to determine the firm's financial worth.
Novocure is rated below average in return on equity category among its peers. It is rated below average in return on asset category among its peers . At this time, Novocure's Return On Equity is relatively stable compared to the past year. Comparative valuation analysis is a catch-all technique that is used if you cannot value Novocure by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.

Novocure Return On Asset vs. Return On Equity

Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.

Novocure

Return On Equity

 = 

Net Income

Total Equity

 = 
-0.51
For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.
Return on Asset or ROA shows how effective is the management of the company in generating income from utilizing all of the assets at their disposal. It is a useful ratio to evaluate the performance of different departments of a company as well as to understand management performance over time.

Novocure

Return On Asset

 = 

Net Income

Total Assets

 = 
-0.083
Return on Asset measures overall efficiency of a company in generating profits from its total assets. It is expressed as the percentage of profits earned per dollar of Asset. A low ROA typically means that a company is asset-intensive and therefore will needs more money to continue generating revenue in the future.

Novocure Return On Asset Comparison

Novocure is currently under evaluation in return on asset category among its peers.

Novocure Profitability Projections

The most important aspect of a successful company is its ability to generate a profit. For investors in Novocure, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Novocure will eventually generate negative long term returns. The profitability progress is the general direction of Novocure's change in net profit over the period of time. It can combine multiple indicators of Novocure, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Last ReportedProjected for Next Year
Accumulated Other Comprehensive Income-5 M-4.7 M
Operating Income-153.4 M-145.8 M
Net Loss-151.8 M-144.2 M
Income Before Tax-118 M-123.9 M
Total Other Income Expense Net45.2 M47.5 M
Net Loss-106.4 M-111.7 M
Net Loss-151.8 M-144.2 M
Income Tax Expense43.1 M45.2 M
Interest Income26.1 M27.4 M
Net Interest Income46.1 M48.4 M
Change To Netincome120.4 M126.4 M
Net Loss(1.41)(1.48)
Income Quality 0.18  0.17 
Net Income Per E B T 1.16  0.89 

Novocure Profitability Driver Comparison

Profitability drivers are factors that can directly affect your investment outlook on Novocure. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Novocure position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Novocure's important profitability drivers and their relationship over time.

Novocure Profitability Trends

Novocure profitability trend refers to the progression of profit or loss within a business. An upward trend means that Novocure's profit has generally increased over time, and a downward profitability trend means profits are declining. Recognizing problems early in profitability trends allows investors to address revenue and cost issues in advance. Investors and analysts usually monitor three types of profitability trends: gross, operating, and net. Gross profit is the difference between revenue and costs of goods sold. Operating profit is Novocure's gross profit minus its overhead. After you account for other unusual revenue, expenses, and costs, you get net profit. Gross profit trends are often a good indicator of future profitability. If you have high gross profit margins, you have a better chance to cover overhead and make money.

Novocure Profitability Drivers Correlations

One of the toughest challenges investors face today is learning how to quickly synthesize and read into endless financial statements and information provided by the company, SEC reporting, and various external parties. Understanding the correlation between Novocure different financial indicators related to revenue and profit generation helps investors identify and prioritize their investing strategies towards Novocure in a much-optimized way. Analyzing correlations between profit drivers that are directly associated with dollar figures is the most effective way to break down Novocure's future profitability.

Novocure Earnings Estimation Breakdown

The calculation of Novocure's earning per share is based on the data from the past 12 consecutive months, used for reporting the company's financial figures. The next projected EPS of Novocure is estimated to be -0.345725 with the future projection ranging from a low of -0.375 to a high of -0.3275. Please be aware that this consensus of annual earnings estimates for Novocure is based on EPS before non-recurring items and includes expenses related to employee stock options.
Last Reported EPS
-0.33
-0.38
Lowest
Expected EPS
-0.345725
-0.33
Highest

Novocure Earnings Projection Consensus

Suppose the current estimates of Novocure's value are higher than the current market price of the Novocure stock. In this case, investors may conclude that Novocure is overpriced and will exhibit bullish sentiment. On the other hand, if the present value is lower than the stock price, analysts may conclude that the market undervalues the equity. These scenarios may suggest that the market is not as efficient as it should be at the estimation time, and Novocure's stock will quickly adjusts to the new information provided by the consensus estimate.
Number of AnalystsHistorical AccuracyLast Reported EPSEstimated EPS for 31st of December 2025Current EPS (TTM)
776.84%
-0.33
-0.345725
-1.61

Novocure Earnings History

Earnings estimate consensus by Novocure analysts from Wall Street is used by the market to judge Novocure's stock performance. Investors also use these earnings estimates to evaluate and project the stock performance into the future in order to make their investment decisions. However, we recommend analyzing not only Novocure's upcoming profit reports and earnings-per-share forecasts but also comparing them to our different valuation methods.

Novocure Quarterly Gross Profit

122.47 Million

As of 01/03/2026, Retained Earnings is likely to grow to about (986.8 M). In addition to that, Retained Earnings Total Equity is likely to drop to about (735.6 M) As of 01/03/2026, Common Stock Shares Outstanding is likely to drop to about 97.4 M. In addition to that, Net Loss is likely to drop to about (111.7 M).
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Novocure's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Hype
Prediction
LowEstimatedHigh
9.9113.1916.47
Details
Intrinsic
Valuation
LowRealHigh
12.2615.5418.82
Details
Naive
Forecast
LowNextHigh
9.6912.9716.26
Details
7 Analysts
Consensus
LowTargetHigh
22.5524.7927.51
Details
Note that many institutional investors and large investment bankers can move markets due to the volume of Novocure assets they manage. They also follow analysts to some degree and often drive overall investor sentiments towards Novocure. With so many stockholders watching consensus numbers, the difference between actual and projected earnings is one of the most critical factors driving Novocure's stock price in the short term.

Novocure Earnings per Share Projection vs Actual

Actual Earning per Share of Novocure refers to what the company shows during its earnings calls or quarterly reports. The Expected EPS is what analysts covering Novocure predict the company's earnings will be in the future. The higher the earnings per share of Novocure, the better is its profitability. While calculating the Earning per Share, we use the weighted ratio, as the number of shares outstanding can change over time.

Novocure Estimated Months Earnings per Share

For an investor who is primarily interested in generating an income out of investing in entities such as Novocure, the EPS ratio can tell if the company is intending to increase its current dividend. Although EPS is an essential tool for investors, it should not be used in isolation. EPS of Novocure should always be considered in relation to other companies to make a more educated investment decision.

Novocure Quarterly Analyst Estimates and Surprise Metrics

Earnings surprises can significantly impact Novocure's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported
Fiscal Date
Estimated EPS
Reported EPS
Surprise
2025-10-23
2025-09-30-0.427-0.330.09722 
2025-07-24
2025-06-30-0.38-0.360.02
2025-06-05
2025-03-31-0.464-0.310.15433 
2025-02-27
2024-12-31-0.36-0.61-0.2569 
2024-10-30
2024-09-30-0.33-0.280.0515 
2024-07-25
2024-06-30-0.41-0.310.124 
2024-05-02
2024-03-31-0.42-0.360.0614 
2024-02-22
2023-12-31-0.52-0.450.0713 
2023-10-26
2023-09-30-0.52-0.460.0611 
2023-07-27
2023-06-30-0.5-0.54-0.04
2023-05-04
2023-03-31-0.32-0.5-0.1856 
2023-02-23
2022-12-31-0.3-0.36-0.0620 
2022-10-27
2022-09-30-0.26-0.250.01
2022-07-28
2022-06-30-0.14-0.23-0.0964 
2022-04-28
2022-03-31-0.18-0.040.1477 
2022-01-10
2021-12-31-0.1-0.25-0.15150 
2021-10-28
2021-09-30-0.07-0.13-0.0685 
2021-07-29
2021-06-300.01-0.14-0.151500 
2021-04-29
2021-03-310.02-0.04-0.06300 
2021-02-25
2020-12-310.120.04-0.0866 
2020-10-29
2020-09-300.030.090.06200 
2020-07-30
2020-06-300.00520.020.0148284 
2020-04-30
2020-03-310.020.040.02100 
2020-02-27
2019-12-310.020.040.02100 
2019-10-31
2019-09-30-0.050.020.07140 
2019-07-25
2019-06-30-0.07-0.010.0685 
2019-05-02
2019-03-31-0.14-0.130.01
2019-02-28
2018-12-31-0.13-0.17-0.0430 
2018-10-25
2018-09-30-0.15-0.130.0213 
2018-07-26
2018-06-30-0.16-0.17-0.01
2018-04-26
2018-03-31-0.13-0.23-0.176 
2018-02-22
2017-12-31-0.11-0.12-0.01
2017-10-26
2017-09-30-0.17-0.130.0423 
2017-07-27
2017-06-30-0.22-0.24-0.02
2017-04-27
2017-03-31-0.24-0.210.0312 
2017-02-23
2016-12-31-0.39-0.260.1333 
2016-11-02
2016-09-30-0.42-0.390.03
2016-07-28
2016-06-30-0.4-0.40.0
2016-05-09
2016-03-31-0.31-0.42-0.1135 
2016-03-01
2015-12-31-0.32-1.08-0.76237 
2015-10-26
2015-09-30-0.33-2.0933-1.7633534 

Use Novocure in pair-trading

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Novocure position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Novocure will appreciate offsetting losses from the drop in the long position's value.

Novocure Pair Trading

Novocure Pair Trading Analysis

The ability to find closely correlated positions to Novocure could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Novocure when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Novocure - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Novocure to buy it.
The correlation of Novocure is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Novocure moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Novocure moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Novocure can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Use Investing Themes to Complement your Novocure position

In addition to having Novocure in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run FinTech Thematic Idea Now

FinTech
FinTech Theme
High long term potential financial entities that are ranging from payment processing, investment management to commercial and investment banking. The FinTech theme has 81 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize FinTech Theme or any other thematic opportunities.
View All  Next Launch

Additional Tools for Novocure Stock Analysis

When running Novocure's price analysis, check to measure Novocure's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Novocure is operating at the current time. Most of Novocure's value examination focuses on studying past and present price action to predict the probability of Novocure's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Novocure's price. Additionally, you may evaluate how the addition of Novocure to your portfolios can decrease your overall portfolio volatility.